Abstract: Embodiments of the present disclosure provide: methods of making a quantum dot, quantum dots, and the like.

Abstract: The disclosure relates to devices, systems and methods that address the variability in immunohistochemistry (IHC) tests that can lead to inaccurate diagnosis or misdiagnosis while maintaining important structural information within the specimen. The devices may include a control region having a control unit including a plurality of substantially homogenous samples and a biological sample region.

Abstract: The present disclosure provides embodiments of a new class of hydroxylated quantum dots. The quantum dots have a hydroxylated coat disposed thereon, and which serves to minimize non-specific cellular binding and to maintain the small size of quantum dot probes. Embodiments of the coated quantum dots of the disclosure are just slightly larger than the diameter of uncoated quantum dots, and are bright with high quantum yields. They are also very stable under both basic and acidic conditions. Embodiments of the hydroxylated quantum dots result in significant reductions in non-specific binding relative to that of carboxylated dots, and to protein and PEG-coated dots. Embodiments of the disclosure are advantageous in a range of biological applications where non-specific binding is a major problem, such as in multiplexed biomarker staining in cells and tissues, detection of biomarkers in body fluid samples (blood, urine, etc.), as well as live cell imaging.

Abstract: The present disclosure provides a method for identifying rare or low-abundant biological entities such as Hodgkin's and Reed-Sternberg cells, circulating tumor cells in peripheral blood, circulating fetal cells, stem cells, somatic cells, HIV-infected T cells, bacteria or viruses in water, adenoviruses, enteroviruses, hepatitis A and E, dengue, Swine Flu, bovine diarrhea, and protozpa/helminthes. The method uses a suite of nanoparticle-conjugated agents to mark biological targets of interest for subsequent fluorescence imaging. In certain embodiments, the nanoparticle-conjugated agents are fluorescent semiconductor nanocrystals conjugated with antibodies with affinity for CD15, CD30, CD45, and Pax5. In certain embodiments, a method is developed to differentiate Hodgkin's and Reed-Sternberg (HRS) cells from amongst surrounding immune cells such as T and B lymphocytes with greater specificity and precision than traditional immunohistochemistry (IHC) for the diagnosis of Hodgkin's lymphoma.

Abstract: Embodiments of the present disclosure provide: methods of making a quantum dot, quantum dots, and the like.

Abstract: The present disclosure provides embodiments of a new class of hydroxylated quantum dots. The quantum dots have a hydroxylated coat disposed thereon, and which serves to minimize non-specific cellular binding and to maintain the small size of quantum dot probes. Embodiments of the coated quantum dots of the disclosure are just slightly larger than the diameter of uncoated quantum dots, and are bright with high quantum yields. They are also very stable under both basic and acidic conditions. Embodiments of the hydroxylated quantum dots result in significant reductions in non-specific binding relative to that of carboxylated dots, and to protein and PEG-coated dots. Embodiments of the disclosure are advantageous in a range of biological applications where non-specific binding is a major problem, such as in multiplexed biomarker staining in cells and tissues, detection of biomarkers in body fluid samples (blood, urine, etc.), as well as live cell imaging.